In clinical practice, the application of angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) reduces proteinuria, and delays CKD progression in patients with large amounts of proteinuria. This evidence concerns the gene ACE and chronic kidney disease.